News

The study, which enrolled 258 chronic obstructive pulmonary disease (COPD) patients, evaluated Icos’ phosphodiesterase 4 (PDE4) inhibitor, IC485, at three doses compared to placebo. “While we are disappointed

The company will concentrate its efforts on a planned phase II/III trial in chronic lymphocytic leukemia (CLL) and a planned a phase I/II trial in HIV, but will

These results follow the previously announced effectiveness on Neuroblastoma cells and are the first of a current series of continuing in vitro tests of PhG-alpha1 targeting a range

The patents cover FHJ Scientific’s proprietary SHBAN compound solution. Scientific evidence and studies by top medical institutions suggest the unique solution may be used in a variety of

The WHO filings take the number of Ranbaxy anti-retrovirals (ARVs) submitted to the authority to five, while the FDA filing, which has been submitted under the FDA’s expedited

The milestone is based on Wyeth and Curis’ continued progress in preclinical development of hedgehog pathway agonists for the treatment of stroke, neurological and other disorders. The milestone

Gabapentin is the AB-rated generic equivalent of Neurontin, a drug used to treat epileptic seizures which is marketed by Warner-Lambert, a unit of Pfizer. On February 11, 2005,

Initial in vitro study results have indicated that PPL-100, a phosphorylated pro-drug of PL-100, is 1,000-fold more water soluble than its precursor. More importantly, pharmacokinetics studies conducted in

The meeting between Protein Design Labs (PDL) and the FDA was to discuss the future development pathway for PDL’s Nuvion (visilizumab) humanized anti-CD3 antibody being developed for the